Print

CEL-SCI (CVM) Reports 146 Patients Enrolled In Its Phase 3 Immunotherapy Head And Neck Cancer Trial  
2/27/2014 9:55:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today reported accelerating progress in patient enrollment in the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Approximately 146 patients have been enrolled in the Phase III study to date.

Help employers find you! Check out all the jobs and post your resume.

//-->